Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer
Journal of Clinical Oncology, 04/18/2012Buyyounouski MK et al.
Interval to biochemical failure (IBF) is the single most robust prognostic factor for prostate cancer mortality (PCM) following radiotherapy (RT) without androgen deprivation therapy. This external validation demonstrates that patients and clinicians can use this information to make decisions about subsequent treatments.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.